ATE263371T1 - Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs - Google Patents

Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs

Info

Publication number
ATE263371T1
ATE263371T1 AT97943330T AT97943330T ATE263371T1 AT E263371 T1 ATE263371 T1 AT E263371T1 AT 97943330 T AT97943330 T AT 97943330T AT 97943330 T AT97943330 T AT 97943330T AT E263371 T1 ATE263371 T1 AT E263371T1
Authority
AT
Austria
Prior art keywords
compliance
consumption
quantitative
markers
medication
Prior art date
Application number
AT97943330T
Other languages
English (en)
Inventor
Michael Kell
Original Assignee
U D Testing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U D Testing Inc filed Critical U D Testing Inc
Application granted granted Critical
Publication of ATE263371T1 publication Critical patent/ATE263371T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/901—Drugs of abuse, e.g. narcotics, amphetamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97943330T 1996-09-17 1997-09-17 Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs ATE263371T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/715,016 US5776783A (en) 1993-11-02 1996-09-17 Method of monitoring therapeutic agent consumption
PCT/US1997/016416 WO1998012557A1 (en) 1996-09-17 1997-09-17 Therapeutic agent with quantitative consumption marker and method of monitoring therapeutic agent consumption

Publications (1)

Publication Number Publication Date
ATE263371T1 true ATE263371T1 (de) 2004-04-15

Family

ID=24872366

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97943330T ATE263371T1 (de) 1996-09-17 1997-09-17 Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs

Country Status (7)

Country Link
US (1) US5776783A (de)
EP (1) EP0944828B1 (de)
JP (1) JP2001507118A (de)
AT (1) ATE263371T1 (de)
CA (1) CA2265795C (de)
DE (1) DE69728418D1 (de)
WO (1) WO1998012557A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3063837B2 (ja) * 1997-09-26 2000-07-12 日本電気株式会社 尿マルチセンサ
US6087182A (en) * 1998-08-27 2000-07-11 Abbott Laboratories Reagentless analysis of biological samples
US6136801A (en) * 1998-12-24 2000-10-24 U. D. Testing, Inc. Therapeutic agent with quantitative consumption marker
US7069226B1 (en) 1999-07-07 2006-06-27 Synetic, Incorporated Prescription data processing system for determining new therapy starts
US20050037374A1 (en) * 1999-11-08 2005-02-17 Melker Richard J. Combined nanotechnology and sensor technologies for simultaneous diagnosis and treatment
JP4773019B2 (ja) * 1999-11-08 2011-09-14 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 薬物の服薬遵守を監視するためのマーカー検出の方法および器具
US20050233459A1 (en) * 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
US6981947B2 (en) 2002-01-22 2006-01-03 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring respiratory gases during anesthesia
US7104963B2 (en) 2002-01-22 2006-09-12 University Of Florida Research Foundation, Inc. Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath
US7062312B2 (en) 2001-01-17 2006-06-13 Pediamed Pharmaceuticals, Inc. Combination and method including a visual marker for determining compliance with a medication regimen
US20030194374A1 (en) * 2001-01-17 2003-10-16 Xanodyne Pharmacal, Inc. Compositions including a visual marker and method of use thereof
WO2002069897A2 (en) * 2001-03-02 2002-09-12 Euro-Celtique, S.A. Method and apparatus for compounding individualized dosage forms
DE10112470B4 (de) * 2001-03-15 2008-02-28 Keller, Ruprecht, Priv.-Doz. Dr.Dr. Verfahren zur Proben-Identifizierung bei einem Säugetier sowie Kit zur Durchführung dieses Verfahrens
US7052854B2 (en) * 2001-05-23 2006-05-30 University Of Florida Research Foundation, Inc. Application of nanotechnology and sensor technologies for ex-vivo diagnostics
EP1405067A2 (de) * 2001-05-23 2004-04-07 University Of Florida Verfahren und vorrichtung zum nachweis illegaler substanzen
EP1393069A1 (de) * 2001-05-24 2004-03-03 The University Of Florida Verfahren und vorrichtung zur rauchaussetzungfeststellung
US20070167853A1 (en) 2002-01-22 2007-07-19 Melker Richard J System and method for monitoring health using exhaled breath
DK1388734T3 (da) * 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
US20060160134A1 (en) * 2002-10-21 2006-07-20 Melker Richard J Novel application of biosensors for diagnosis and treatment of disease
CA2504452A1 (en) * 2002-10-31 2004-05-21 Sheryl E. Siegel Pharmaceutical identification
DE10253664B4 (de) 2002-11-18 2005-02-03 Gauchel, Gisela, Dr. Diagnoseverfahren
US7585680B2 (en) * 2003-08-28 2009-09-08 Marshfield Medical Research And Education Foundation Method and device for monitoring medication usage
US20050191757A1 (en) * 2004-01-20 2005-09-01 Melker Richard J. Method and apparatus for detecting humans and human remains
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
US8296162B1 (en) 2005-02-01 2012-10-23 Webmd Llc. Systems, devices, and methods for providing healthcare information
US20060257883A1 (en) * 2005-05-10 2006-11-16 Bjoraker David G Detection and measurement of hematological parameters characterizing cellular blood components
US20060277063A1 (en) * 2005-06-01 2006-12-07 Travis Leonardi Preventive healthcare program with low-cost prescription drug benefit patient enrollment system and method
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders
EP2001534A4 (de) * 2006-03-07 2013-07-03 Univ Florida System zur überwachung der einhaltung von arzneimitteldosen
US7914460B2 (en) * 2006-08-15 2011-03-29 University Of Florida Research Foundation, Inc. Condensate glucose analyzer
US8380530B2 (en) * 2007-02-02 2013-02-19 Webmd Llc. Personalized health records with associative relationships
US8067243B2 (en) * 2008-09-03 2011-11-29 Oregon Medical Laboratories Methods and systems for analyzing medication levels in a sample
WO2011099984A1 (en) * 2010-02-11 2011-08-18 Harry Leider Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
US20140342380A1 (en) * 2011-11-21 2014-11-20 Daniel Saal Verifying the source of biological samples; method, composition and kit therefor
JP2017518814A (ja) * 2014-05-28 2017-07-13 ユニバーシティ・オブ・シンシナティ 発汗モニタリング及び薬物送達の制御
ES2958613T3 (es) 2014-06-18 2024-02-12 Ruma Gmbh Método para la identificación de una muestra biológica de un mamífero, composición para el uso en este método y estuche para la realización de este método
EP3106876B1 (de) 2015-06-19 2022-12-07 F. Hoffmann-La Roche AG Feststoffabfallentsorgung
WO2017192686A1 (en) 2016-05-03 2017-11-09 Synapse Biosciences, LLC Methods and dose packs for monitoring medication adherence
EP3713477B1 (de) 2017-11-21 2022-07-06 MX3 Diagnostics, Inc. Speicheltestsystem und verfahren
JP2022508683A (ja) 2018-10-11 2022-01-19 エムエックススリー・ダイアグノスティクス・インコーポレイテッド イオン選択センサ
EP3782096B1 (de) 2019-07-04 2023-06-07 Ruma GmbH Ortsunabhängige einnahmekontrolle
US11701036B2 (en) 2019-07-10 2023-07-18 MX3 Diagnostics, Inc. Saliva test strip and method
WO2021146407A1 (en) 2020-01-15 2021-07-22 MX3 Diagnostics, Inc. Assessment of biomarker concentration in a fluid
US11703436B2 (en) 2020-01-30 2023-07-18 MX3 Diagnostics, Inc. Biological fluid sample assessment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2564247A (en) * 1947-08-18 1951-08-14 Richard M Carson Method of testing urine to determine pregnancy
US3856469A (en) * 1973-01-02 1974-12-24 Syva Corp Interferant removal from amphetamine immunoassay
US3901655A (en) * 1973-12-26 1975-08-26 American Cyanamid Co Urine toxicology control
US4104367A (en) * 1976-10-13 1978-08-01 Hoffmann-La Roche Inc. Radioimmunoassay for methadone
US4196185A (en) * 1978-06-05 1980-04-01 Hoffmann-La Roche Inc. Immunoassay for phencyclidine
JPH0698032B2 (ja) * 1987-01-23 1994-12-07 財団法人野田産業科学研究所 クレアチンもしくはクレアチニンの測定法及びこれらの測定用試薬
US5137692A (en) * 1990-12-11 1992-08-11 Robert Fritz Nitrogen test kit for physical training
US5179027A (en) * 1991-01-10 1993-01-12 Fisher Murray M Method employing chemical markers and kit for verifying the source and completeness of urine samples for testing for the presence of drugs of abuse
US5547878A (en) * 1993-11-02 1996-08-20 Kell; Michael Method of monitoring patient compliance with medications prescriptions

Also Published As

Publication number Publication date
EP0944828A4 (de) 1999-09-29
JP2001507118A (ja) 2001-05-29
CA2265795A1 (en) 1998-03-26
CA2265795C (en) 2006-03-07
WO1998012557A1 (en) 1998-03-26
DE69728418D1 (de) 2004-05-06
EP0944828B1 (de) 2004-03-31
EP0944828A1 (de) 1999-09-29
US5776783A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
ATE263371T1 (de) Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs
Smilkstein et al. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol
Clayton et al. Comparison of sexual functional in clinical and nonclinical populations using the changes in Sexual Functioning Questionnaire (CSFQ)
Chang et al. Intra-hippocampal lidocaine injections impair acquisition of a place task and facilitate acquisition of a response task in rats
Kalso et al. Pain relief from intra-articular morphine after knee surgery: a qualitative systematic review
Dalby et al. Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin
Ruoff et al. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study
Steiner et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study
Loyd et al. Sex differences in μ-opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia
Kranzler et al. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo‐controlled clinical trial
Nelson Managing treatment-resistant major depression
Espejo et al. Prefrontocortical dopamine depletion induces antidepressant-like effects in rats and alters the profile of desipramine during Porsolt's test
Balla et al. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release
IL133265A0 (en) Heparanase specific molecular probes and their use in research and medical applications
Gattaz et al. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients
Wagenmann et al. The effect of terfenadine on unilateral nasal challenge with allergen
ATE378015T1 (de) System zur behandlung eines patienten mit einem medikament zur optimierung der therapie und zur verhinderung eines negativen nebeneffektes
Haney et al. Smoked cocaine discrimination in humans: effects of gabapentin
Witkiewitz et al. Reductions in World Health Organization risk drinking levels as a primary efficacy end point for alcohol clinical trials: a review
Bisaga et al. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence
ATE437963T1 (de) In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase
Lee et al. Effect of modulated electrohyperthermia on the pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers
Lan et al. Enhancing effects of morphine on methamphetamine‐induced reinforcing behavior and its association with dopamine release and metabolism in mice
Hull et al. Long-term anticoagulant therapy in patients with venous thrombosis
Daniel et al. Methadone-induced attenuation of the effects of delta 9-tetrahydrocannabinol on temporal discrimination in pigeons.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties